Procaine amide (Pronestyl) was administered to patients with auricular fibrillation and flutter in an attempt to restore sinus rhythm. Thirteen of 20 patients with auricular fibrillation had sinus rhythm re-established. Several of the patients who were not converted with procaine amide were later restored to sinus rhythm with quinidine.
OR MANY YEARS the restoration of sinus rhythm in patients with auricular fibrillation and auricular flutter has been limited primarily to the use of quinidine and its allies. Other agents have occasionally been used without too satisfactory clinical effects.
In animal experiments, procaine hydrochloride has been shown to exert a markedly depressant action on conduction of the cardiac impulse'. Procaine hydrochloride has been employed locally and parenterally in treating cardiac arrhythmias arising during surgical procedures in anesthetized patients and has been tried in various clinical instances of spontaneous cardiac irregularities'. While sometimes useful under the former circumstances, its central stimulating effects have precluded its application in the unanesthetized patient.
Recently a procaine derivative, the amide analogue of procaine has been introduced3. This agent, procaine amide (Pronestyl), is free of central nervous stimulating effects in the dosages used and is applicable in unanesthetized patients. The experimental data of Newman and Clark4' demonstrated that procaine amide exerts a slowing effect on conduction and produces a decrease of irritability of auricular muscle of the rabbit and the dog. These observations have led us to explore the sphere of usefulness of the drug in the conversion of 
MATERIAL AND METHODS
Our material and the therapy used are listed in table 1 . There were 20 patients with auricular fibrillation; of these, 13 had chronic auricular fibrillation. The latter term was arbitrarily applied to those patients who were known to have auricular fibrillation for two weeks or more. Their ages ranged from 37 to 71 years and the duration of the arrhythmia from 16 days to more than three years. Five of these patients had rheumatic heart disease and seven had hypertensive and/or arteriosclerotic heart disease.
Of seven patients with paroxysmal auricular fibrillation, five had hypertensive and/or arteriosclerotic heart disease and one patient (case 2) with no previous evidence of heart disease developed auricular fibrillation one day following an appendectomy.
All three patients with auricular flutter had arteriosclerotic heart disease; in two the auricular flutter was paroxysmal while the duration of the arrhythmia was unknown in the third patient.
Except for five of the patients with paroxysmal auricular fibrillation and one patient with paroxysmal auricular flutter, all were receiving digitalis at the time conversion was attempted. Two of the patients with auricular flutter were partially digitalized. Procaine amide was given orally in the majority of cases, intramuscularly in one case each of paroxysmal and chronic auricular fibrillation, and intravenously in two cases of auricular flutter. Initially there was some variation in the oral doses, but subsequently the following schedule was generally employed: 500 mg. every two hours for five doses on the first day; 750 mg. every two hours for five doses on the second dav and similar 2W0 mg. increments on the following days until toxicity or regular sinus rhythm occurred. The highest single dose was 1500 mg., and the highest dosage in one Circulation, Volume VI, July 1952 This patient, after at least six months of auricular fibrillation, had been converted to sinus rhythm with quinidine six weeks previously. Omission of maintenance therapy resulted in a recurrence of fibrillation which was present for about two weeks prior to procaine amide therapy. day was 11.5 Gm. in case 8. Six patients with chronic auricular fibrillation unsuccessfully treated with procaine amide were later treated with quinidine sulfate (table 3). Case 19 was started on quinidine 15 hours after his last dose of procaine amide. In all others who received quinidine, 36 or more hours were allowed to elapse after the last dose of procaine amide before quinidine therapy was started.
RESULTS
All seven patients with eight bouts of paroxysmal auricular fibrillation who received procaine amide were converted to sinus rhythm (tables 1 and 2). The duration of auricular fibrillation prior to therapy ranged from two hours in case 3 to at least 10 days in case 6 (table 1). Cases 3, 4 and 5 returned to sinus rhythm following relatively small doses (500 to 1000 mg.) of the drug and the possibility of spontaneous conversion cannot be excluded.
However, larger doses of procaine amide were required for normalization of rhythm in the four other instances. Case 6 was restored to sinus rhythm, but when the maintenance dose of procaine amide was decreased to 500 mg. four times a day auricular fibrillation recurred. Procaine amide was then again used successfully in higher doses to re-establish sinus rhythm. In case 7, sinus rhythm was restored after intramuscular therapy.
Of 13 patients with chronic auricular fibrillation who received procaine amide six returned to sinus rhythm (tables 1 and 2). Except for case 20 , there was electrocardiographic evidence of the presence of auricular fibrillation of at least two weeks duration in all patients. The duration of the arrhythmia in case 20 is unknown but it was thought to have been present several months prior to therapy. Of five cases with chronic auricular fibrillation with rheumatic heart disease only one was converted to sinus rhythm with procaine amide although the medication was given in sufficient quantity (table 1) to produce toxic manifestations in three of four failures. In three of the rheumatic patients who were not converted with procaine amide, quinidine sulfate was given later and was successful in restoring sinus rhythm in all (table 3) . Of eight patients in whom chronic auricular fibrillation was associated with arteriosclerotic and/or hypertensive heart disease, sinus rhythm was restored by procaine amide in five. Case 18 was converted a second time when a reduction in his maintenance therapy was followed by a recurrence of auricular fibrillation. All three failures in the hypertensive arteriosclerotic group were subsequently tried briefly on quinidine sulfate (table 3) . One patient (case 13) returned to sinus rhythm.
The results of procaine amide treatment in the cases of auricular flutter, used intravenously in two cases and orally in one, will be mentioned IN AURICULAR FIBRILLATION was diagnosed clinically. In all other patients the auricular mechanism was proved by electro- 22 ).
An untoward increase of ventricular rate under procaine amide medication was observed in 6 instances. Cases 9, 16 ( fig. 1 c) (e) 5/4/51, lead I: lleavily digitalized. Auricular standstill (due to complete S-A block) and nodal rhythm, rate 65. Electrical alternans due to intermittent complete (QRS 0.18 second), superimposed on a persistent incomplete (QRS 0.11), right bundle branch system block. manifestations encountered were dizziness, luciiiationis. Although in some instances (cases nausea, vomiting, and in one case visual hal-8 and 19) the amount of procaine amide given was unusually high and was extended to the point of clinical intolerance, in none was ectopic impulse formation or impairment of intraventricular conduction observed which could be ascribed to the action of the drug. In two instances (cases 16 and 22, figs. lc and 4) a right sided conduction defect present before medication was started, showed no further impairment. The QRS prolongation seen in case 23 ( fig. 3 ) at the peak of the procaine amide effect, disappeared immediately with con--version to nodal rhythm and may, therefore, be ascribed to the excessively high ventricular rate during auricular flutter.
COMMENT After screening numerous compounds for possible use in the therapy of cardiac arrhythmia, Mark and co-workers carried out extensive studies with procaine amide.3-7 While these authors advocated its use in arrhythmias of ventricular origin, Newman and Clark subsequently demonstrated that the drug also had a very definite effect on the conduction and irritability of the auricle of the rabbit and dog.4' Studies with intravenous procaine amide demonstrated a very definite slowing of the fibrillatory rate of the human auricle.3 7 8 The drug has been successfully used by others7' in cases of paroxysmal auricular fibrillation. The uniformly good success in restoring sinus rhythm in our seven patients with recent onset of auricular fibrillation is in keeping with these findings. However, six of the 13 patients with chronic auricular fibrillation were also restored to sinus rhythm. This result is somewhat better than anticipated since a number of observers5' 7, [8] [9] [10] [11] [12] [13] have reported the absence of conversions in patients with chronic auricular fibrillation given intravenous procaine amide. It is quite likely that the greater success in more recent investigations using oral procaine amidels' 15 and in the present study was a result of the higher dosage schedules employed. Refleeting the latter, four of the six patients with chronic auricular fibrillation who were converted had toxic symptoms just prior to, or at the time of, restoration of regular sinus rhythm. Since procaine amide produces its peak blood level approximately one to two hours after each oral dose3, we feel that a two hour schedule is to be preferred in attempting conversion.
To simplify the observation of all patients receiving procaine amide, we generally omitted night time medication and recommended therapy the followrinig morning at the next higher dose schedule. Procaine amide was not only effectively used orally and intravenously but in two patients, who could not take oral medication, the drug was successfully employed by intramuscular administration.
Although weight for weight quinidine is more potent than procaine amide,4' 16 The electrocardiographic alterations found during our procaine amide studies are in accord with previous investigations as far as changes of the auricular mechanism,'4 the auricular and/or ventricular rate3' 7, 8, 14 and the effect on Q-T duration' 7 are (oncerned. The same discordanit effect on auricular and ventricular action (slowting of the former and acceleration of the latter) was seen under procaine amide as was described years ago by Rothberger20 and LewN'is21' 22 ill their studies on the effect of quinine and quinidiine on auricular flutter and fibrillation. This includes the deleterious increase of ventricular rate by production of full A-V conduction as seen in two of our cases wNith auricular flutter. Prolongation of the Q-T interval was seen in about one third of cases treated orally by procaine amide. The shortening effect on the "electrical systole" of digitalis may explain the lack of appearance of Q-T prolongation ill the greater part of our material consisting primarily of cases with chronic auricular fibrillation.
The increase in the ventricular rate may be marked in patients with auricular fibrillation and particularly auricular flutter who receive procaine amide, especially if no digitalis has been given. In view of the danger of prolonged, rapid ventricular rates, particularly in the presence of associated heart disease, it is best to give adequate digitalis therapy prior to an attempt at conv\ersioni.
The exact mechanism of the action of procaine amide on the auricular and ventricular myocardium is still obscure and requires further experimental clarificationi. The striking similarity between (1ninidine and procaine2 and its amide in their clinical action and effects upon the electrocardiogram invites speculation upon a possible similar mode of action. Prolongation of the refractory period of the isolated rabbit auricle by procaine amide has been demonstrated,4 andc a similar effect onl the ventricular myocardium is suggested by the prolongation of the Q-T interval following clinical application of procaine amide. However, the appearance of persistent nodal rhythm after interruption of experimentally produced auricular fibrillation, as previously reported,23 as well as its appearance in one of our cases cannot be explained by such a mechanism alone. It is possible that, for unknown reasons, secondary mechanisms may become prevalent ill certain instances, like stimulation of subsidiary automatic center and/or a depressing action on impulse transmission ill the auricles.* The latter mechanism has been especially stressed ill recent studies24 on the action of quinidii e ill auricular arrhythmias. The similarity to quinidine is further supported by observations of unusually high rates of A-V conduction (276 in case 23), which were ascribed ill the case of quinidine to its paralysing effect upon the vagi. 21 SUMMARY AND CONCLUSIONS 1. Twenty cases of auricular fibrillation and three cases of auricular flutter were treated with procaine amide (Pronestyl) ill an attempt to restore sinus rhythm.
2. The attempt proved successful in all instances of paroxysmal auricular fibrillation, in 6 of 13 cases with chronic auricular fibrillation and in two of three cases of auricular flutter. The dosage used ranged from a single dose of 500 mg. in a case of paroxysmal auricular fibrillation to 11.5 Gm. in a day given to a patient with chronic auricular fibrillation. 3. In no instance were there electrocardiographic manifestations of toxicity ini the present series. In two instances slowing of the rate of auricular flutter by procaine amide with transient 1: 1 A-V conduction and aberrant intraventricular conduction imitated the electrocardiographic pattern of ventricular tachycardia of ectopic origin.
4. A striking similarity between procaine amide and quinidine was found in their clinical action as well as in their effect upon the electro-* Such a complex mechanism was apparently under action and effected by massive digitalization in case 22, figure 4e , and produced complete S-A block, nodal rhvtthm and electrical alternation.
cardiogram. Although this suggests very strongly a similar mode of action of both drugs, further experimental proof is needed.
